Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature

References

• Li YY , Jones SJM . Drug repositioning for personalized medicine. Genome Med. 2012; 4: 27.
   PubMed Web of Science ®Google Scholar
• Lekka E , Deftereos SN , Persidis A , Persidis A , Andronis C . Literature analysis for systematic drug repurposing: a case study from Biovista. Drug Discov Today Ther Strateg. 2012; 8: 103–8.
   Google Scholar
• Persidis A . The benefits of drug repositioning. Drug Discov World. 2011; 12: 9–12.
   Google Scholar
• Sleigh SH , Barton CL . Repurposing strategies for therapeutics. Pharm Med. 2010; 24: 151–9.
   Google Scholar
• Smith RB . Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg. 2011. 8:131–7.
   Google Scholar
• Business Insights reports. Successful strategies for drug repositioning: low-risk approaches to indication expansion and lifecycle extension for established molecules. London (UK): Business Insights . 2011; 101. Report No.: BI00050–002.
   Google Scholar
• Padhy BM , Gupta YK . Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011; 57: 153–60.
   PubMed Web of Science ®Google Scholar
• Holt RIG , Barnett AH , Bailey CJ . Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Met. 2010; 12: 1048–57.
   PubMed Web of Science ®Google Scholar
• Tomer G . Prevailing against cost-leader competitors in the pharmaceutical industry. J Generic Med. 2008; 5: 305–14.
   Google Scholar
• Horbal JM , Bernstein JA . Azelastine HCL: a review of the old and new formulations. Clin Med Insights Ther. 2010; 2: 427–37.
   Google Scholar
• Tran HT , Kluger J , Chow MSS . Focus on IV amiodarone: a new formulation for acute arrhythmia treatment. Formulary. 1995; 30: 509–19.
   Google Scholar
• Huskamp HA , Busch AB , Domino ME , Normand SLT . Antidepressant reformulations: who uses them, and what are the benefits?. Health Aff. 2009; 28: 734–45.
   Web of Science ®Google Scholar
• Kingma I , Ludwin D , Dandavino R , Wolff JL , Loertscher R , Beauregard-Zollinger L . Economic analysis of Neoral in de novo renal transplant patients in Canada. Clin Transplant. 1997; 11: 42–8.
   Web of Science ®Google Scholar
• Clay PG , Taylor TAH , Glaros AG , McRae MP , Williams C , McCandless D . “One pill, once daily”: what clinicians need to know about Atripla (trademark). Ther Clin Risk Manag. 2008; 4: 291–302.
   PubMedGoogle Scholar
• Brereton N , Bodger K , Kamm MA , Hodgkins P , Yan S , Akehurst R . A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ. 2010; 13: 148–61.
   PubMedGoogle Scholar
• Guerrini R . Valproate as a mainstay of therapy for pediatric epilepsy. Pediatr Drugs. 2006; 8: 113–29.
   PubMedGoogle Scholar
• Insa R . Drug repositioning: filling the gap. EBR Eur Biopharm Rev. 2010;(Summer):; 44–8.
   Google Scholar
• Tobinick EL . The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009; 22: 119–25.
   PubMed Web of Science ®Google Scholar
• Sirota M , Dudley JT , Kim J , Chiang AP , Morgan AA , Sweet-Cordero A . Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011; 3: 96ra77.
   PubMed Web of Science ®Google Scholar
• Huang R , Southall N , Wang Y , Yasgar A , Shinn P , Jadhav A . The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011; 3: 80ps16.
   PubMed Web of Science ®Google Scholar
• Von Eichborn J , Murgueitio MS , Dunkel M , Koerner S , Bourne PE , Preissner R . PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 2011; 39: D1060–D6.
   PubMed Web of Science ®Google Scholar
• Pawar VK , Kansal S , Asthana S , Chourasia MK . Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory consideration. Expert Opin Drug Deliv. 2012; 9: 551–65.
   PubMed Web of Science ®Google Scholar
• Jin G , Fu C , Zhao H , Cui K , Chang J , Wong STC . A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res. 2012; 72: 33–44.
   PubMed Web of Science ®Google Scholar
• Hermann AMM . Drug repositioning: extracting added value from prior R&D investments. Insight pharma reports.
   Google Scholar
• Datamonitor reports. Lifecycle management strategies: reformulation: success hinges on delivering significant improvement in disease outcome. USA (NY): Datamonitor; 2012, 30 p. Report No.: HC00246–001.
   Google Scholar
• Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov. 2002;1: 753–68.
   Google Scholar
• Datamonitor reports. Drug repositioning strategies: serendipity by design. USA (NY): Datamonitor. 2008; 97. Report No.: DMHC2400.
   Google Scholar
• Yuryev A , Kotelnikova E , Daraselia N . Ariadne's chemeffect and pathway studio knowledge base. Expert Opin Drug Discov. 2009; 4: 1307–18.
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A , Garcia-Lopez P , Herrera LA , Medina-Franco JL , Gonzalez-Fierro A , Candelaria M . The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer. 2008; 7: 82.
   PubMed Web of Science ®Google Scholar
• Should (black down triangle) dabigatran replace warfarin for stroke prevention in AF?. Drug Ther Bull. 2011; 49: 114–7.
   Google Scholar
• Baldinger SL , Chow MSS . Focus on anticoagulants: Warfarin's new indication for cardiovascular disease and enoxaparin's new indication for knee replacement surgery. Formulary. 1995; 30: 657–76.
   Google Scholar
• Schmier JK , Covert DW , Robin AL . First-year treatment patterns among new initiators of topical prostaglandin analogs. Curr Med Res Opin. 2009; 25: 851–8.
   PubMed Web of Science ®Google Scholar
• Gupta SK . Duragesic (registered trademark) D-TRANS (registered trademark), a new matrix delivery system for fentanyl: progress in a new technology. Douleurs. 2005; 6: 105–8.
   Google Scholar